Sartorius Stedim Biotech (SDMHF) Projected to Post Earnings on Thursday

Sartorius Stedim Biotech (OTCMKTS:SDMHF) is anticipated to announce its results before the market opens on Thursday, October 22nd. Analysts expect Sartorius Stedim Biotech to post earnings of $1.37 per share and revenue of $857.36 million for the quarter.

Sartorius Stedim Biotech Price Performance

SDMHF opened at $235.00 on Wednesday. The company’s 50 day simple moving average is $229.45 and its 200-day simple moving average is $210.36. Sartorius Stedim Biotech has a one year low of $178.30 and a one year high of $264.30.

Analyst Ratings Changes

Separately, UBS Group raised Sartorius Stedim Biotech to a “buy” rating in a report on Thursday, August 20th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Sartorius Stedim Biotech presently has an average rating of “Moderate Buy”.

About Sartorius Stedim Biotech

Sartorius Stedim Biotech SA is a France-based provider of technologies and services used by the biopharmaceutical industry. The company supports the development and manufacture of biologic medicines, including vaccines, therapeutic proteins, and other advanced biological products.

Its portfolio includes single-use bioprocessing equipment and consumables, bioreactors and fermentation systems, filtration and purification technologies, fluid-management products, cell-culture solutions, and laboratory instruments.